ÂÜÀòÂÒÂ×

Krishnan Nandabalan has a rich work experience spanning several companies in the healthcare and pharmaceutical industry. Krishnan is currently the Founder, Chairman, President, and CEO of Invea Therapeutics, a role they began in November 2021. Prior to this, they held multiple leadership positions at InveniAI since 2017, including President, CEO, and Founder. Krishnan also served as a Board Member for the same company.

Before joining InveniAI, Krishnan was involved with BioXcel, LLC, where they held the roles of Board Member and President and Co-Founder, starting from September 2005. Krishnan also served as a Board Member for BioXcel Therapeutics, Inc. starting from April 2017.

Earlier in their career, Krishnan worked at Genaissance Pharmaceuticals as the VP of Corporate Development. Krishnan began their professional journey at CuraGen Corporation as a Group Leader in Functional Genomics, a position they held from January 1995 to September 1998.

Krishnan Nandabalan began their education at Tamil Nadu Agricultural University from 1978 to 1984, where they obtained both their BSc and MSc degrees in Microbiology. Krishnan then pursued further studies at the Indian Institute of Science (IISc) from 1984 to 1989, completing their Ph.D. in Biochemistry and Molecular Biology. Following this, they joined the University of Kentucky as a Post-Doctoral Fellow from 1989 to 1990. Finally, Krishnan Nandabalan attended Yale University as a Post-Doctoral Fellow from 1990 to 1994, specializing in Yeast Genetics.